According to recent reports in the diabetes news, biopharmaceutical company CureDM Inc. have made a significant breakthrough in the development of their type 1 and type 2 diabetes treatment HIP.
HIP (Human proIslet Peptide) is designed to prevent, ameliorate or even reverse diabetes . The company have reportedly stabilised the treatment to work out the appropriate dosage for humans. The company developed the peptide from a specific human gene that populated the pancreas with islet cells.
The CEO of CureDM, Lorain Upham, reportedly commented: "Meeting this milestone has a significant impact on the commercial value of Human proIslet Peptide. Not only does this mean lower costs associated with the manufacture and commercialization, but also potentially better safety and tolerability outcomes in human trials."
The company have applied with the FDA for approval of human studies.
New diabetes therapy steps forward
Thu, 01 May 2008
Recommended links
Join the community here and nowDiabetes based financial services
Diabetes book reviews
Check the forum
Diabetes not to blame in crash
Higher risk of heart attack for diabetics
New therapy is effective against type 1 diabetes in mice
Gene therapy super drug could combat diabetes
Diabetes therapy does not damage the brain
Diabetic vision improved through oxygen therapy
Patients with diabetes and heart conditions could use statin therapy
Insulin Pump Therapy for Diabetes Sufferers
Psychotherapy as diabetes treatment for teens
Brain important in therapy for diabetes
Diabetes therapy could bring hope of cure
Diabetes therapy effective long-term
Stem cell diabetes therapy
Diabetes stem cell therapy effective
Nerve therapy for diabetics has 'striking' results
Chemotherapy for diabetes
